Cost-benefit analysis of a new alcohol biomarker, carbohydrate deficient transferrin, in a chronic illness primary care sample

Kathryn Sullivan Dillie, Marlon Mundt, Michael French, Michael F. Fleming

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Carbohydrate Deficient Transferrin (CDT) is a new alcohol biomarker recently approved by the Food and Drug Administration for alcohol screening. Limited information is available on the economic benefits of alcohol biomarkers. Our objective was to conduct a cost-benefit analysis (CBA) of the CDT test in a primary care sample of patients being treated for diabetes and hypertension. Methods: A decision tree was created using data from national surveys, published literature, and two brief intervention trials conducted in primary care settings. The decision tree was used to estimate the costs and benefits of CDT under different scenarios. Results: For the base case, utilizing CDT in addition to patient self-report resulted in an increase from 28 to 53 problem drinking cases identified out of 70 cases screened. With increased detection and subsequent intervention, the average medical and legal costs were far lower in the CDT arm of the study. When these avoided costs were incorporated into the model, an overall savings of $212.30 per patient was realized with CDT testing. Monte Carlo analysis also indicated a trend toward cost savings, with a mean cost savings of approximately $353 and a range of $1,619 in savings to $450 in costs for 1,000 simulations of the decision tree model. Conclusion: This CBA suggests that the addition of routine CDT screening to patient self-report may provide positive net economic benefits in primary care settings.

Original languageEnglish (US)
Pages (from-to)2008-2014
Number of pages7
JournalAlcoholism: Clinical and Experimental Research
Volume29
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Cost benefit analysis
Biomarkers
Cost-Benefit Analysis
Primary Health Care
Chronic Disease
Alcohols
Decision Trees
Decision trees
Costs
Cost Savings
Costs and Cost Analysis
Self Report
Screening
Economics
United States Food and Drug Administration
Medical problems
carbohydrate-deficient transferrin
Drinking
Hypertension
Testing

Keywords

  • Alcohol Biomarkers
  • Alcohol Screening
  • CDT
  • Cost-Benefit Analysis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Toxicology

Cite this

Cost-benefit analysis of a new alcohol biomarker, carbohydrate deficient transferrin, in a chronic illness primary care sample. / Dillie, Kathryn Sullivan; Mundt, Marlon; French, Michael; Fleming, Michael F.

In: Alcoholism: Clinical and Experimental Research, Vol. 29, No. 11, 11.2005, p. 2008-2014.

Research output: Contribution to journalArticle

@article{e16a88fa0da249958ad4717952ad45e2,
title = "Cost-benefit analysis of a new alcohol biomarker, carbohydrate deficient transferrin, in a chronic illness primary care sample",
abstract = "Background: Carbohydrate Deficient Transferrin (CDT) is a new alcohol biomarker recently approved by the Food and Drug Administration for alcohol screening. Limited information is available on the economic benefits of alcohol biomarkers. Our objective was to conduct a cost-benefit analysis (CBA) of the CDT test in a primary care sample of patients being treated for diabetes and hypertension. Methods: A decision tree was created using data from national surveys, published literature, and two brief intervention trials conducted in primary care settings. The decision tree was used to estimate the costs and benefits of CDT under different scenarios. Results: For the base case, utilizing CDT in addition to patient self-report resulted in an increase from 28 to 53 problem drinking cases identified out of 70 cases screened. With increased detection and subsequent intervention, the average medical and legal costs were far lower in the CDT arm of the study. When these avoided costs were incorporated into the model, an overall savings of $212.30 per patient was realized with CDT testing. Monte Carlo analysis also indicated a trend toward cost savings, with a mean cost savings of approximately $353 and a range of $1,619 in savings to $450 in costs for 1,000 simulations of the decision tree model. Conclusion: This CBA suggests that the addition of routine CDT screening to patient self-report may provide positive net economic benefits in primary care settings.",
keywords = "Alcohol Biomarkers, Alcohol Screening, CDT, Cost-Benefit Analysis",
author = "Dillie, {Kathryn Sullivan} and Marlon Mundt and Michael French and Fleming, {Michael F.}",
year = "2005",
month = "11",
doi = "10.1097/01.alc.0000187606.54854.db",
language = "English (US)",
volume = "29",
pages = "2008--2014",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Cost-benefit analysis of a new alcohol biomarker, carbohydrate deficient transferrin, in a chronic illness primary care sample

AU - Dillie, Kathryn Sullivan

AU - Mundt, Marlon

AU - French, Michael

AU - Fleming, Michael F.

PY - 2005/11

Y1 - 2005/11

N2 - Background: Carbohydrate Deficient Transferrin (CDT) is a new alcohol biomarker recently approved by the Food and Drug Administration for alcohol screening. Limited information is available on the economic benefits of alcohol biomarkers. Our objective was to conduct a cost-benefit analysis (CBA) of the CDT test in a primary care sample of patients being treated for diabetes and hypertension. Methods: A decision tree was created using data from national surveys, published literature, and two brief intervention trials conducted in primary care settings. The decision tree was used to estimate the costs and benefits of CDT under different scenarios. Results: For the base case, utilizing CDT in addition to patient self-report resulted in an increase from 28 to 53 problem drinking cases identified out of 70 cases screened. With increased detection and subsequent intervention, the average medical and legal costs were far lower in the CDT arm of the study. When these avoided costs were incorporated into the model, an overall savings of $212.30 per patient was realized with CDT testing. Monte Carlo analysis also indicated a trend toward cost savings, with a mean cost savings of approximately $353 and a range of $1,619 in savings to $450 in costs for 1,000 simulations of the decision tree model. Conclusion: This CBA suggests that the addition of routine CDT screening to patient self-report may provide positive net economic benefits in primary care settings.

AB - Background: Carbohydrate Deficient Transferrin (CDT) is a new alcohol biomarker recently approved by the Food and Drug Administration for alcohol screening. Limited information is available on the economic benefits of alcohol biomarkers. Our objective was to conduct a cost-benefit analysis (CBA) of the CDT test in a primary care sample of patients being treated for diabetes and hypertension. Methods: A decision tree was created using data from national surveys, published literature, and two brief intervention trials conducted in primary care settings. The decision tree was used to estimate the costs and benefits of CDT under different scenarios. Results: For the base case, utilizing CDT in addition to patient self-report resulted in an increase from 28 to 53 problem drinking cases identified out of 70 cases screened. With increased detection and subsequent intervention, the average medical and legal costs were far lower in the CDT arm of the study. When these avoided costs were incorporated into the model, an overall savings of $212.30 per patient was realized with CDT testing. Monte Carlo analysis also indicated a trend toward cost savings, with a mean cost savings of approximately $353 and a range of $1,619 in savings to $450 in costs for 1,000 simulations of the decision tree model. Conclusion: This CBA suggests that the addition of routine CDT screening to patient self-report may provide positive net economic benefits in primary care settings.

KW - Alcohol Biomarkers

KW - Alcohol Screening

KW - CDT

KW - Cost-Benefit Analysis

UR - http://www.scopus.com/inward/record.url?scp=29044435772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044435772&partnerID=8YFLogxK

U2 - 10.1097/01.alc.0000187606.54854.db

DO - 10.1097/01.alc.0000187606.54854.db

M3 - Article

VL - 29

SP - 2008

EP - 2014

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 11

ER -